• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24117 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2010     Committee for New Health Technology Assessment (CNHTA) [Liver cancer prognostic marker(OncoHepa)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Literature search and evidence assessment to examine the effects of regulations for minimum volumes (acc. to §6 [5], line 2 of the directive on outpatient treatment in hospitals acc. to §116b Social Code Book V) - Rapid report]
2020     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Literature review on efficacy and safety of ultraviolet light and ozone for surface disinfection (Update)]
2011     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Literature review of organisational and patient aspects in HTA]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Literature bibliographic search protocols adapting them to the different search outputs]
2012     Norwegian Knowledge Centre for the Health Services (NOKC) [List size and quality of care among GPs within The Regular General Practitioner Scheme]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisocabtagene maraleucel (DLBCL, PMBCL and FL3B) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisocabtagene maraleucel (DLBCL, HGBL, PMBCL and FL3B, second line) – Addendum to Commission A23-48]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisocabtagene maraleucel (DLBCL, HGBCL, PMBCL and FL3B, each after one prior therapy) – Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisdexamfetamine (ADHD) - Benefit assessment according to §35a Social Code Book V]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisdexamfetamine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Liraglutide in obese and overweight patients]
2008     The Regional Health Technology Assessment Centre (HTA-centrum) [Liquid-based cytology for screening of precursors of cervical cancer]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Liquid biopsy utility in the colorectal cancer's management stages I-IV]
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Liquid biopsy in the diagnosis of ovarian cancer – a compilation of scientific literature]
2024     Andalusian Health Technology Assessment Area (AETSA) [Liquid biopsy in lung neoplasms: diagnosis, prognosis and treatment adequacy]
2020     Canary Health Service [Liquid biopsy for the detection of ovarian or endometrial cancer in samples taken from the Pap smear: PapSEEK]
2008     Committee for New Health Technology Assessment (CNHTA) [Liqui-Prep TM]
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Liposuction for the removal of subcutaneous (large) lipomas]
2021     Norwegian Institute of Public Health (NIPH) [Liposuction (lipectomy) for the treatment of fat accumulation caused by chronic lymphoedema]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Liposomal combination of cytarabine and daunorubicin (acute myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Lipogems® System for autologous adipose tissue-derived mesenchymal stem cells transfer in orthopedic conditions]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Lipoedema – diagnosis, treatment, and experiences]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Lipid metabolism disorders: review of the indications of fat free dietetic products and nutritional alternatives with regularly consumed foodstuffs]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Linzagolix (uterine fibroids) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Linzagolix (endometriosis) – Benefit assessment according to §35a Social Code Book V]
2013     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Linear accelerator radiosurgery for trigeminal neuralgia]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Linagliptin - Re-assessment of benefit according to § 35a, Para. 5b, Social Code Book V (dossier assessment)]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Linagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Linaclotide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lifestyle interventions with the aim of lowering blood sugar levels: Evidence report for the S3 guideline on gestational diabetes mellitus (GDM) – diagnosis, treatment and follow-up care]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Levonorgestrel-releasing intrauterine device as contraceptive method in women of childbearing age]
2010     Institute for Clinical Effectiveness and Health Policy (IECS) [Levonorgestrel-releasing intrauterine device (IUD) for patients with hypermenorrhea]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Levofloxacin/dexamethasone (inflammation and infection associated with cataract surgery) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Levofloxacin/dexamethasone (inflammation and infection associated with cataract surgery) - Addendum to Commission A21-12]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Levels of medical intervention -- levels of care]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Levels of care: norms and quality standards]
2006     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Leukotriene receptor antagonists in patients with asthma]
2009     The Swedish Council on Health Technology Assessment (SBU) [Leukocytapheresis in inflammatory bowel disease (primarily ulcerative colitis)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (prophylaxis of cytomegalovirus reactivation and disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (prophylaxis of CMV reactivation and disease after stem cell transplantation) - Addendum to Project A23-139]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (CMV prophylaxis after stem cell transplantation) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (CMV prophylaxis after kidney transplant) – Benefit assessment according to §35a Social Code Book V]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Less invasive surfactant administration]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Lenvatinib for iodine-refractory differentiated thyroid cancer]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (renal cell carcinoma): benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (hepatocellular carcinoma) - Addendum to Commission A18-57]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (endometrial carcinoma) - Addendum to Commission A21-162]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [LEG TEST. Multi centre testing of the Lively Legs program for promoting compliance with compression therapy and prescribed exercise in leg ulcer patients]
2018     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Left ventricular assist device (LVAD) as destination therapy]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir (hepatitis C) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir (Addendum to Commission A14-44)]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Lecanemab in Alzheimer’s Disease]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lebrikizumab (atopic dermatitis) – Benefit assessment according to §35a Social Code Book V]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Lead extraction of pacemaker or implantable cardiac defibrillator leads using laser excimer]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [LDL-Apheresis in familial hypercholesterolemia and hypertriglyceridemia]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lazertinib (NSCLC, first line, in combination with amivantamab) – Benefit assessment according to §35a Social Code Book V]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Lattice radiotherapy in the curative or palliative treatment of deep, large-volume tumors and metastatic or unresectable disease]
2023     Center for Drug Evaluation (CDE) [Latest trend in consumption and utilization of schedule I and II controlled drugs - a nationwide population-based data in Taiwan
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Latanoprost/netarsudil (primary open-angle glaucoma and ocular hypertension) – Addendum to Commission A22-129]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Latanoprost/netarsudil (glaucoma) - Benefit assessment according to §35a Social Code Book V]
2001     Basque Office for Health Technology Assessment (OSTEBA) [Last trends in genetic therapy]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lasmiditan (migraine) – Benefit assessment according to §35a Social Code Book V]
2011     The Swedish Council on Health Technology Assessment (SBU) [Laser-induced interstitial thermal therapy for liver metastases]
2013     Haute Autorite de sante (HAS) [Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Laser treatment for benign prostatic hyperplasia. Proposal of assessment indicators]
2009     The Swedish Council on Health Technology Assessment (SBU) [Laser technology for removal of caries]
2021     Andalusian Health Technology Assessment Area (AETSA) [Laser interstitial thermal therapy for patients with refractory epilepsy: safety and effectiveness. A systematic review]
1995     Basque Office for Health Technology Assessment (OSTEBA) [Laser excimer in ophthalmology]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Laser angioplasty of coronary arteries]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Larotrectinib (solid tumours) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Larotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) - Addendum to Commission A19-90]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Laronidase (Aldurazyme) for the treatment of mucopolysaccharidosis I]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Lapatinib or trastuzumab in combination with aromatase Inhibitors for hormone receptor positive/ErbB2-positive breast cancer]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Lapatinib (Tyverb) for the treatment of metastatic breast cancer]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Laparoscopy versus laparotomy in treatment of early stage endometrial cancer: a multi-centre cost-effectiveness study]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Laparoscopic vertical sleeve gastrectomy vs. laparoscopic Roux-en Y gastric bypass for the treatment of obesity]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Laparoscopic versus conventional surgery in colorectal cancer]
2011     The Regional Health Technology Assessment Centre (HTA-centrum) [Laparoscopic surgery in kidney neoplasms]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Laparoscopic surgery in colorectal cancer : quality of life, psychological impact and patient satisfaction]
2009     Norwegian Knowledge Centre for the Health Services (NOKC) [Laparoscopic surgery for benign gynaecological disease]
2004     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Laparoscopic surgery effectiveness and safety vs open surgery in colorectal cancer]
2010     The Regional Health Technology Assessment Centre (HTA-centrum) [Laparoscopic peritoneal lavage for patients with perforated diverticulitis]
2013     The Netherlands Organisation for Health Research and Development (ZonMw) [Laparoscopic ileocolic resection versus infliximab treatment of recurrent distal ileitis in Crohn's disease: a randomized multicenter trial]
2009     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Laparoscopic hysterectomy and lymphadenectomy efficacy and safety in endometrial cancer]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Laparoscopic and endoscopic cooperative surgery for gastrointestinal tumor]
2009     Committee for New Health Technology Assessment (CNHTA) [Laparoscopic adjustable gastric banding for morbid obesity]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Laparoscopic (non robotic) radical prostatectomy versus open radical prostatectomy in localized prostate cancer]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lanadelumab (hereditary angioedema) - Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lanadelumab (hereditary angioedema, 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lanadelumab - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Laminar air flow in the operating room to prevent hip and knee arthroplasty infections]